Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 195

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 195
---
 Board; • Reviewing and updating of the Compensation Discussion and Analysis section of our proxy statement for our 2025 Annual Meeting of Stockholders; and • Supporting on other ad hoc matters. The terms of Compensia’s engagement include reporting directly to the Compensation Committee and to the Compensation Committee Chair. In fiscal 2024, Compensia did not provide any services to us other than those described above. The Compensation Committee has evaluated Compensia’s independence pursuant to the listing standards of Nasdaq and the relevant SEC rules and has determined that no conflict of interest has arisen as a result of the work performed by Compensia. Competitive Positioning For each of the past ten years, the Compensation Committee has directed its external compensation consultant to conduct a comparative study and report on compensation levels and practices relative to industry peers, including a competitive assessment of our executive compensation program as compared to the market data for base salaries, target total cash compensation, long-term incentive compensation and target total direct compensation. Typically, the findings of this study are presented to the Compensation Committee by the compensation consultant in conjunction with the Compensation Committee’s annual review of our executive compensation program. Because the biotechnology sector is dynamic, the comparator group used by the Compensation Committee to assess the competitive positioning of the compensation of our executive officers is updated annually to ensure that peer companies continue to meet the established criteria. For purposes of its review of our executive compensation Table of Contents 2025 PROXY STATEMENT Executive Compensation 35

program in fiscal 2024, the Compensation Committee directed Compensia to update the compensation peer group reflecting the competitive market for executive talent based on the following criteria: • Publicly-held, U.S. biotechnology companies; • Companies with lead assets that are in mid to late clinical stage or early commercialization stage; • Companies with market capitalizations between 0.25x to 4.0x our market capitalization at the time of the peer selection; and • Companies with between 92 to 1,311 employees. The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies. Consideration was also given to the frequency or infrequency with which a company was identified as a peer with other peer companies. For fiscal 2024, the compensation peer group was generated in the first quarter of fiscal 2024 and consisted of the following companies: ACADIA Pharmaceuticals, Inc. Insmed Amicus Therapeutics Intellia Therapeutics Apellis Pharmaceuticals Ionis Pharmaceuticals Arcus Biosci